Cases 1–26

  • Jawad Ahmad


A 51-year-old Caucasian man presents to your outpatient clinic with abnormal liver enzymes for several years. He is accompanied by his wife. He is asymptomatic without evidence of jaundice, fever or chills, weight loss. He has no past medical history and is on no prescribed medication. He denies any over the counter or herbal medicines. He does not drink significantly (once or twice a year) but smokes a packet of cigarettes a day and works as a salesman. He is happily married with grown up children. There is no history of intravenous drug use or cocaine. His father had Hodgkin’s lymphoma.


Celiac Disease Primary Biliary Cirrhosis Primary Sclerosing Cholangitis Autosomal Dominant Polycystic Kidney Disease Choledochal Cyst 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med 2000;342:1266–71.PubMedCrossRefGoogle Scholar
  2. 2.
    Drebber U, Kasper HU, Ratering J, et al. Hepatic granulomas: histological and molecular pathological approach to differential diagnosis – a study of 442 cases. Liver Int 2008;28:828–34.PubMedCrossRefGoogle Scholar
  3. 1.
    Tait N, Richardson AJ, Muguti G, et al. Hepatic cavernous haemangioma: a 10 year review. Aust N Z J Surg 1992;62:521.PubMedCrossRefGoogle Scholar
  4. 2.
    Gandolfi L, Leo P, Solmi L, et al. Natural history of hepatic haemangiomas: clinical and ultrasound study. Gut 1991;32:677.PubMedCrossRefGoogle Scholar
  5. 3.
    Popescu I, Ciurea S, Brasoveanu V, et al. Liver hemangioma revisited: current surgical indications, technical aspects, results. Hepatogastroenterology 2001;48:770.PubMedGoogle Scholar
  6. 1.
    Angulo P, Lindor KD. Primary sclerosing cholangitis. Hepatology 1999;30:325.PubMedCrossRefGoogle Scholar
  7. 2.
    Mendes FD, Jorgensen R, Keach J, et al. Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. Am J Gastroenterol 2006;101:2070.Google Scholar
  8. 3.
    Lindor KD, Kowdley KV, Luketic VA, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009;50:808.PubMedCrossRefGoogle Scholar
  9. 1.
    Newman KD, Torres VE, Rakela J, et al. Preliminary experience with a combined hepatic resection–fenestration procedure. Ann Surg 1990;212:30–7.PubMedCrossRefGoogle Scholar
  10. 2.
    Kirchner GI, Rifai K, Cantz T, et al. Outcome and quality of life in patients with polycystic liver disease after liver or combined liver–kidney transplantation. Liver Transpl 2006;12:1268–77.PubMedCrossRefGoogle Scholar
  11. 1.
    Krawitt EL. Autoimmune hepatitis. N Engl J Med 2006;354:54.PubMedCrossRefGoogle Scholar
  12. 2.
    Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008;48:169–76.PubMedCrossRefGoogle Scholar
  13. 3.
    Czaja AJ, Freese DK. Diagnosis and treatment of autoimmune hepatitis. Hepatology 2002;36:479.PubMedCrossRefGoogle Scholar
  14. 1.
    Rubio-Tapia A, Murray JA. The liver in celiac disease. Hepatology 2007;46:1650–58.PubMedCrossRefGoogle Scholar
  15. 2.
    Novacek G, Miehsler W, Wrba F, et al. Prevalence and clinical importance of hypertransaminasemia in celiac disease. Eur J Gastroenterol Hepatol 1999;11:283–8.PubMedCrossRefGoogle Scholar
  16. 1.
    Todani T, Watanabe Y, Narusue M, et al. Congenital bile duct cysts: classification, operative procedures, and review of 37 cases including cancer arising from choledochal cyst. Am J Surg 1977;134:263–9.PubMedCrossRefGoogle Scholar
  17. 2.
    Singham J, Yoshida EM, Scudamore CH. Choledochal cysts: classification and pathogenesis. Can J Surg 2009;52:434–40.PubMedGoogle Scholar
  18. 1.
    Dalton HR Bendall R, Ijaz S, et al. Hepatitis E: an emerging infection in developed countries. Lancet Infect Dis 2008;8:698–709.Google Scholar
  19. 1.
    Wanless IR, Mawdsley C, Adams R. On the pathogenesis of focal nodular hyperplasia of the liver. Hepatology 1985;5:1194.PubMedCrossRefGoogle Scholar
  20. 2.
    Shamsi K, De Schepper A, Degryse H, Deckers F. Focal nodular hyperplasia of the liver: radiologic findings. Abdom Imaging 1993;18:32.PubMedCrossRefGoogle Scholar
  21. 3.
    Scalori A, Tavani A, Gallus S, et al. Oral contraceptives and the risk of focal nodular hyperplasia of the liver: a case-control study. Am J Obstet Gynecol 2002;186:195.PubMedCrossRefGoogle Scholar
  22. 1.
    Litin SC, O’Brien JF, Pruett S, et al. Macroenzyme as a cause of unexplained elevation of aspartate aminotransferase. Mayo Clin Proc 1987;62:681.PubMedCrossRefGoogle Scholar
  23. 2.
    Trimester S, Douglas DD. Development of macro-aspartate aminotransferase in a patient undergoing specific allergen injection immunotherapy. Am J Gastroenterol 2005;100:243–5.CrossRefGoogle Scholar
  24. 1.
    Aithal GP, Thomas JA, Kaye PV, et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008;135:1176–84.PubMedCrossRefGoogle Scholar
  25. 2.
    Chalasani NP, Sanyal AJ, Kowdley KV, et al. Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp Clin Trials 2009;30:88–96.PubMedCrossRefGoogle Scholar
  26. 1.
    Crum NF. Epstein–Barr virus hepatitis: case series and review. South Med J 2006;99:544–7.PubMedCrossRefGoogle Scholar
  27. 2.
    Méndez-Sánchez N, Aguilar-Domínguez C, Chávez-Tapia NC, et al. Hepatic manifestations of Epstein–Barr viral infection. Ann Hepatol 2005;4:205–9.PubMedGoogle Scholar
  28. 3.
    Shaukat A, Tsai HT, Rutherford R, et al. Epstein–Barr virus induced hepatitis: an important cause of cholestasis. Hepatol Res 2005;33:24–6.PubMedCrossRefGoogle Scholar
  29. 1.
    Just-Nübling G, Korn S, Ludwig B, et al. Primary cytomegalovirus infection in an outpatient setting – laboratory markers and clinical aspects. Infection 2003;31:318–23.PubMedGoogle Scholar
  30. 2.
    Kanno A, Abe M, Yamada M, et al. Clinical and histological features of cytomegalovirus hepatitis in previously healthy adults. Liver Int 2008;17:129–32.CrossRefGoogle Scholar
  31. 1.
    Czaja AJ, Carpenter HA, Santrach PJ, et al. Autoimmune cholangitis within the spectrum of autoimmune liver disease. Hepatology 2000;31:1231–8.PubMedCrossRefGoogle Scholar
  32. 2.
    Czaja AJ, Bayraktar Y. Non-classical phenotypes of autoimmune hepatitis and advances in diagnosis and treatment. World J Gastroenterol 2009; 15: 2314–28.PubMedCrossRefGoogle Scholar
  33. 1.
    Grazioli L, Federle MP, Brancatelli G, et al. Hepatic adenomas: imaging and pathologic findings. Radiographics 2001;21:877.PubMedGoogle Scholar
  34. 2.
    Rooks JB, Ory HW, Ishak KG, et al. Epidemiology of hepatocellular adenoma. The role of oral contraceptive use. JAMA 1979;242:644.PubMedCrossRefGoogle Scholar
  35. 3.
    Ault GT, Wren SM, Ralls PW, et al. Selective management of hepatic adenomas. Am Surg 1996;62:825.PubMedGoogle Scholar
  36. 1.
    Cogrel O, Doutre MS, Marliere V, Beylot-Barry M, Couzigou P, Beylot C. Cutaneous sarcoidosis during interferon alfa and ribavirin treatment of hepatitis C virus infection: two cases. Br J Dermatol 2002;146:320–4.PubMedCrossRefGoogle Scholar
  37. 2.
    Hoffmann RM, Jung MC, Motz R, et al. Sarcoidosis associated with interferon-alpha therapy for chronic hepatitis C. J Hepatol 1998;28:1058–63.PubMedCrossRefGoogle Scholar
  38. 3.
    Adla M, Downey KK, Ahmad J. Hepatic sarcoidosis associated with pegylated interferon alfa therapy for chronic hepatitis C: case report and review of literature. Dig Dis Sci 2008;53:2810–2.PubMedCrossRefGoogle Scholar
  39. 1.
    Kaplan MM. Primary biliary cirrhosis. N Engl J Med 2005;353:1261.PubMedCrossRefGoogle Scholar
  40. 2.
    Long RG, Scheuer PJ. Sherlock presentation and course of asymptomatic primary biliary cirrhosis. Gastroenterology 1977;72(6):1204–7.PubMedGoogle Scholar
  41. 3.
    Solaymani-Dodaran M, Aithal GP, Card T, et al. Risk of cardiovascular and cerebrovascular events in primary biliary cirrhosis: a population-based cohort study. Am J Gastroenterol 2008;103:2784.Google Scholar
  42. 1.
    Lee WM. Drug-induced hepatotoxicity. N Engl J Med 2003;349:474.PubMedCrossRefGoogle Scholar
  43. 1.
    Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001;344:495.PubMedCrossRefGoogle Scholar
  44. 2.
    Piccinino F, Sagnelli E, Pasquale G, Giusti G. Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies. J Hepatol 1986;2:165.PubMedCrossRefGoogle Scholar
  45. 3.
    Rockey DC, Caldwell SH, Goodman ZD, et al. Liver biopsy. Hepatology 2009;49:1017.PubMedCrossRefGoogle Scholar
  46. 1.
    Blachar A, Federle MP, Brancatelli G. Primary biliary cirrhosis: clinical, pathologic, and helical CT findings in 53 patients. Radiology 2001;220:329–36.PubMedGoogle Scholar
  47. 2.
    Kuiper EM, Zondervan PE, Buuren HR. Paris criteria are effective in diagnosis of primary biliary cirrhosis and autoimmune hepatitis overlap syndrome. Clin Gastroenterol Hepatol 2010;8(6):530–4.PubMedCrossRefGoogle Scholar
  48. 3.
    Yokokawa J, Saito H, Kanno Y, et al. Overlap of primary biliary cirrhosis and autoimmune hepatitis: characteristics, therapy, and long term outcomes. J Gastroenterol Hepatol 2010;25:376–82.PubMedCrossRefGoogle Scholar
  49. 1.
    Nathwani RA, Pais S, Reynolds TB, et al. Serum alanine aminotransferase in skeletal muscle diseases. Hepatology 2005;41:380–2.PubMedCrossRefGoogle Scholar
  50. 2.
    Akmal M, Massry SG. Reversible hepatic dysfunction associated with rhabdomyolysis. Am J Nephrol 1990;10:49–52.PubMedCrossRefGoogle Scholar
  51. 3.
    Skenderi KP, Kavouras SA, Anastasiou CA, et al. Exertional rhabdomyolysis during a 246-km continuous running race. Med Sci Sports Exerc 2006;38:1054–7.PubMedCrossRefGoogle Scholar
  52. 1.
    Hoofnagle JH. Reactivation of hepatitis B. Hepatology 2009;49:S156–65.PubMedCrossRefGoogle Scholar
  53. 2.
    Loomba R, Rowley A, Wesley R, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008;148:519–28.PubMedGoogle Scholar
  54. 3.
    Lok AS, Liang RH, Chiu EK, et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991;100:182–8.PubMedGoogle Scholar
  55. 1.
    Everhart JE, Lok AS, Kim HY, et al. Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Gastroenterology. 2009;137:549–57.PubMedCrossRefGoogle Scholar
  56. 2.
    Wiley TE, Brown J, Chan J. Hepatitis C infection in African Americans: its natural history and histological progression. Am J Gastroenterol 2002;97:700–6.PubMedCrossRefGoogle Scholar
  57. 3.
    Freedman ND, Everhart JE, Lindsay KL, et al. Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology 2009;50:1360–9.PubMedCrossRefGoogle Scholar
  58. 4.
    Yano M, Kumada H, Kage M, et al. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996;23:1334–40.PubMedCrossRefGoogle Scholar
  59. 1.
    Roberts EA, Schilsky ML. A practice guideline on Wilson disease. Hepatology 2003;37:1475.PubMedCrossRefGoogle Scholar
  60. 2.
    Roberts EA, Schilsky ML. Diagnosis and treatment of Wilson disease: an update. Hepatology 2008;47:2089.Google Scholar
  61. 1.
    McManus DP, Zhang W, Li J, et al. Echinococcosis. Lancet 2003;362:1295–304.PubMedCrossRefGoogle Scholar
  62. 2.
    Menezes da Silva A. Hydatid cyst of the liver – criteria for the selection of appropriate treatment. Acta Trop 2003;85:237–42.PubMedCrossRefGoogle Scholar
  63. 3.
    Nasseri Moghaddam S, Abrishami A, Malekzadeh R. Percutaneous needle aspiration, injection, and reaspiration with or without benzimidazole coverage for uncomplicated hepatic hydatid cysts. Cochrane Database Syst Rev 2006;19(2):CD003623.Google Scholar
  64. 1.
    Giallourakis CC, Rosenberg PM, Friedman LS. Liver in heart failure. Clin Liver Dis 2002;6:947–67.PubMedCrossRefGoogle Scholar
  65. 2.
    Myers RB, Spodick DH. Constrictive pericarditis: clinical and pathophysiologic characteristics. Am Heart J 1999;138:219–32.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Division of Liver Diseases Recanati-Miller Transplantation InstituteMount Sinai School of MedicineNew YorkUSA

Personalised recommendations